Despite the impact of the ongoing COVID-19 pandemic, the Japanese urological device market will grow steadily through 2029, largely due to the growing elderly population. However, the market will be negatively affected in the short term by the global COVID-19 pandemic and many facilities already have the expensive capital equipment needed for stone management and BPH procedures, which will limit purchases of new systems.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in Japan across a 10-year period.
The COVID-19 pandemic will negatively impact the Japan urological device market.
Which types of procedures and device segments will be most impacted?
At what pace is the urological device market expected to recover?
Internationally, a great deal of negative publicity has emerged surrounding the safety of synthetic mesh products.
How will this impact the genitourinary mesh market in Japan?
How have physicians in the Japanese market reacted compared to those in the US?
Positive changes in reimbursement have influenced the adoption of premium-priced urological devices in Japan.
Which markets are most affected by these reimbursement changes?
What impact has this change had on physician preferences?
How are companies responding to these changes?
The markets for capital equipment, such as holmium laser systems and ESWL systems, have essentially reached saturation in Japan.
What are some factors that particularly impact the Japanese market for these devices?
What is the revenue outlook for these devices?
How many of these devices are currently installed in Japan, and how many new units will be installed through the forecast period?
- Urological Devices - Market Insights - Japan
Author(s): Sumit Jain, MS Pharm
Sumit Jain is an analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.